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Abstract 
Background: Nodding syndrome (NS) is a severe neuropsychiatric syndrome of an unknown etiology affecting chil‑
dren and adolescents mostly in Eastern Africa. Symptoms of NS and catatonia seem to overlap. We investigated the 
presence and types of catatonic symptoms in NS and their response to one or two doses of lorazepam, the first‑line 
treatment for catatonia.
Methods: A cross‑sectional descriptive study with systematic assessment of catatonia in 33 patients with NS using 
a modified version of the Bush Francis Catatonia Rating Scale. Sixteen patients met criteria for catatonia and were 
observed in an open and uncontrolled study to examine the effects of one or two doses of lorazepam in them.
Results: Sixteen of 33 patients with NS had an average of 5 catatonia symptoms and met criteria for catatonia. The 
highest scores were found for mutism, staring, poor eating/drinking, stupor, and grimacing. Excitement, rigidity, 
negativism and impulsivity had lower scores. None of the children had echolalia or echopraxia. In 6 children, there 
was a reduction of more than 50 % in catatonia ratings, representing a positive response to lorazepam. Three out of 
six children whose catatonia ratings did not change after the first dose, responded after administration of a second 
double dose. There were no unusual or critical side‑effects.
Conclusions: About half of a selected sample of children with NS met criteria for catatonia. Catatonia scores 
decreased in most patients after one or two doses of lorazepam. Larger, longer, and controlled studies are warranted 
to assess the prevalence of catatonia in NS and to assess the use of lorazepam in NS through its effects on catatonia.
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Background
Nodding syndrome (NS) is a neurological condition 
of unknown etiology that has affected over 10,000 or 
more children and adolescents aged 3–18  years in the 
sub-Saharan countries of Uganda, Tanzania and South 
Sudan [1–3]. NS is a clinical constellation of symptoms 
that comprises of head nodding, often associated with 
cognitive impairment, malnutrition, other multiple sei-
zure types and progressive neurological deterioration 
[4]. In Uganda, NS has occurred in epidemic propor-
tions especially in the post-conflict northern districts of 
Lamwo, Kitgum and Pader with over 170 deaths reported 
[4] and few other cases reported in Amuru, Gulu, Lira 
and Oyam districts indicating increasing geographical 
coverage.
Results from a single-stage cluster survey conducted in 
three districts in northern Uganda among children aged 
5–18 years gives an estimated prevalence of 6.8 probable 
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NS cases (95 % CI 5.9–7.7) per 1000 [5]. The hallmark of 
NS is the ‘head nods’ that have been attributed to atonic 
seizures [1]. NS is complicated by seizures which may 
be recurrent and severe generalized tonic–clonic, myo-
clonic, focal or atypical absence types. Furthermore there 
is deterioration in social interaction and communica-
tion skills coupled with movement and posture activity 
limitations, malnutrition, and behavioral and emotional 
disturbances [6]. A number of classifications have been 
proposed to classify patients with NS, Winkler et al. [2] 
classified them as either head nodding only or head nod-
ding plus, if they also had other seizure types. At the first 
international scientific meeting on NS held in Uganda in 
July 2012 [4], a new consensus case definition was drawn 
to classify them into suspect, probable or confirmed 
cases. To date, in addition to an undetermined etiology, 
there is no diagnostic test and NS lacks a definitive treat-
ment although anti-epileptic drugs, nutritional supple-
ments, antidepressants are thought to improve aspects of 
the disorder [4].
Catatonia is a unique syndrome characterized by spe-
cific motor signs, at times life-threatening when aggra-
vated by autonomic dysfunction and fever, yet treatable if 
recognized early [7, 8]. The syndrome occurs worldwide 
including in resource-limited settings and responds well 
to benzodiazepines as first-line treatment [9, 10]. The 
syndrome also occurs in children and adolescents [11, 
12] with a variety of associated conditions including neu-
rological disorders [13, 14].
Signs observed in pediatric and adult catatonia, regard-
less of associated medical or neurological condition, 
include immobility or severe motor slowing, sometimes 
alternating with excessive motor activity that is mostly 
purposeless and not influenced by external stimuli, 
extreme negativism (pervasive refusal to comply with 
requests including refusal to drink and eat), reduced 
speech or mutism, repetitive movements or stereotypy, 
echolalia, echopraxia, and other peculiarities of volun-
tary movement [15].
Some of the neuropsychiatric features [16] of NS are 
similar to what is seen in pediatric catatonia. Patients 
with NS seem to exhibit several catatonic symptoms 
which range from: the head nods when nodding is viewed 
as a form of tic, slowing of movements, immobility alter-
nating with purposeless agitation, muteness, repetitive 
movements, staring, posturing, grimacing, social with-
drawal, negativism (including active or passive refusal 
to eat and drink), and urinary incontinence. Aggressive 
and self-injurious behavior and hallucinations have also 
been reported both in children with catatonia and NS. 
No prior studies have formally assessed the presence 
of catatonia in NS patients using standardized criteria. 
It is therefore important to ascertain the presence of 
catatonia in patients with NS to clarify the neuropsychi-
atric impairment and to find new therapeutic approaches.
Given the clinical similarities between NS and catato-
nia, one may postulate that NS may be a form of pediat-
ric catatonia and that circumstances in Northern Uganda 
and surrounding areas provide a crucible of risk factors, 
both medical and psychological, leading to catatonic 
development and impairment [17]. Pediatric catatonia is 
treatable and very responsive to benzodiazepines and in 
refractory cases, to electroconvulsive therapy [11, 12, 15], 
also in cases associated with neurological conditions [13, 
14].
A positive catatonia test (i.e., when a 50 % reduction of 
symptoms follows acute administration of a benzodiaz-
epine) would verify the presence of catatonia and serve 
as a possible treatment option in this poorly understood 
neurological disorder.
In this pilot study, we examined a convenient sam-
ple of children and adolescents with nodding syndrome 
for catatonic symptoms using standardized criteria. We 
also tested whether oral lorazepam (LZP) administered 
to those who qualified to have pediatric catatonia would 
alleviate symptoms. We hypothesized that children and 
adolescents with nodding syndrome meet clinical criteria 
for pediatric catatonia and children and adolescents with 
nodding syndrome having symptoms of pediatric catato-
nia would have a positive response (>50  % reduction of 




This was a cross-sectional descriptive study of catatonia 
in NS patients in Northern Uganda and an open label 
pilot study of using one or two doses of lorazepam as a 
catatonia test.
Study setting
The study was conducted in Pader District, situated in 
Northern Uganda (one of the three districts reported to 
be most affected by NS) in the villages of Bolo-Laming 
and Lagotoywech. Pader was formerly part of Kitgum 
District and borders Lamwo to the northwest, Kitgum 
District to the northeast, Gulu in the west, Agago in the 
east and Lira and Otuke in the South (see Additional 
file 1: Figure S1). Pader forms part of the northern Ugan-
dan region that has been the site of a protracted (over 
20  years) rebel insurgency that displaced over one mil-
lion people into internally displaced camps [16]. Fol-
lowing the return of peace the security situation has 
significantly improved with disbandment of the inter-
nally displaced people’s (IDP) camps and most of the 
population returning to their ancestral homes. The 
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district headquarters at Pader are located approximately 
130 km (81 miles), by road, northeast of Gulu, the larg-
est city in the sub-region. The district population is over 
481,400 persons. The primary occupation of both men 
and women following resettlement is agriculture, live-
stock and small business.
Study participants
Young people aged 10–21  years, who fulfilled the NS 
diagnosis according to the consensus definition by inter-
national NS researchers [4], who presented with two or 
more catatonic items from a list of ten preselected com-
mon catatonia symptoms coined the Kampala Catatonia 
Panel (see section on assessment of catatonia) and whose 
caregivers gave written informed consent, were consecu-
tively recruited. Children without a caregiver to provide 
the history of the child, a history of having used a benzo-
diazepine drug in the past 48 h, or having a concurrent 
acute illness (e.g. febrile illness, pneumonia) at time of 
assessment were excluded.
Study definitions
Young people were defined as individuals between ages 
10 and 24 years [18].
Epilepsy was defined as recurrence of, at least, two 
epileptic seizures with or without a positive response to 
treatment with any anti-epileptic drug [19].
A suspected NS case was defined as reported head nod-
ding (repetitive involuntary drops of the head towards 
the chest on two or more occasions) in a previously nor-
mal person.
A probable NS case was defined as a suspected case 
with age of onset at 3–18 years and a frequency of nod-
ding of 5–20 nods per minute, plus at least one of six 
minor criteria.
A confirmed NS case was defined as a probable case 
with a documented nodding episode that was either 
observed and recorded by a trained health-care worker, 
videotaped, or documented with video electroencepha-
lography or electromyography as atonic seizures (See 
Additional file 2: Table S1).
Procedure of enrolment and study measurements
In March 2013, AKM travelled to Pader District where 
a single-stage cluster survey to determine the preva-
lence of NS in Uganda using the new consensus case 
definition was being conducted by the Centers for Dis-
ease Control (CDC) Atlanta with collaboration from the 
Ugandan Ministry of Health. The children with probable 
NS had earlier been identified by village health workers 
during a house-to-house census conducted in July 2012 
in the northern Ugandan district of Pader. During the 
census, Village health workers had queried the heads of 
households whether anyone in their households had or 
had ever had head nodding. All children with probable 
NS within the district were then mobilized to attend 
the respective treatment centers during this time. The 
screening and treatment centers for NS were initially 
set up in March 2012 in the northern Ugandan districts 
of Kitgum, Lamwo, and Pader by the Uganda Minis-
try of Health, where most NS cases have been reported. 
At these centers the probable NS cases receive medical 
treatment such as anticonvulsants, nutritional rehabili-
tation in form of therapeutic feeds, speech and language 
therapy, physiotherapy, psychosocial support for behav-
ioral problems and appropriate care for any other exist-
ing co-morbidities. The details of this treatment have 
previously been described [6].
Each child with probable NS brought to the treat-
ment center in Bolo-Laming and Lagotoywech were fur-
ther assessed by staff of the census medical team using 
a standardized questionnaire to further classify the cases 
based on the consensus criteria. Medical and family 
social history, were obtained, anthropometric measure-
ments were taken and the developmental and cognitive 
function of the child assessed. When the census team had 
completed their investigations, the children with con-
firmed NS were screened by the principal investigator 
(AKM) for possible catatonia using a modified version 
of the Bush-Francis Catatonia Rating Scale, (BFCRS), a 
23-item, standardized instrument for catatonia diagno-
sis and assessment of severity [20] that is used to meas-
ure treatment response [21]. Before obtaining written 
informed consent from the caregivers AKM, explained to 
the caregivers via an interpreter the risks and benefits of 
the procedure.
All consecutive cases who qualified for the inclusion 
criteria were recruited following written informed con-
sent from the caregiver.
Assessment for catatonia
When using the BFCRS, catatonia is usually diagnosed 
when two or more items on the first 14 items are present. 
Scores on all 23 items are between 0 and 69 and gauge 
severity. In this study, a more stringent diagnosis of cata-
tonia was used, and patients qualified for a diagnosis of 
catatonia if 2 or more items of 10 items selected from the 
14 BFCRS screening items were present.
These 10 items were selected from the 14 BFCRS 
screening items as the most important and obvious 
symptoms of catatonia. Four BFCRS screening items, i.e., 
waxy flexibility, verbigeration, posturing, and manner-
isms were not included as they are less frequently found 
in catatonic patients [20] and require a more elaborate 
assessment that was difficult to do in the field setting 
of this study. Severity was assessed using a Likert-scale 
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of 0–5 (0 =  absent, 1 = maybe present; 2 =  a little bit; 
3 = clearly present; 4 = a lot; 5 = extreme), with a maxi-
mum score of 50. The 10-item list used to assess for cata-
tonia in this study formed the Kampala Catatonia Panel 
(KCP) test and the items selected are listed in Table 1.
Sample size
No sample size calculations were employed since this was 
a pilot study and the number of persons included were 
a random sample of convenience comprising a propor-
tion of all the patients that had been confirmed to have 
NS by the census team at these respective centers. The 
two selected villages made up part of a parish (a parish 
contains multiple villages). The census team selected 
30 parishes by single-stage cluster sampling with prob-
ability proportional to size from the northern Ugandan 
districts of Kitgum, Lamwo, and Pader, where most NS 
cases have been reported. In each parish 20–30 children 
with reported head nodding were selected using simple 
random sampling without replacement and invited with 
their caregivers to a central meeting point for verification.
The intervention
All the children with confirmed NS that had two or more 
of the symptoms on the KCP were recruited by AKM to 
undergo the catatonia test using oral Lorazepam EG® 
(n.v. Eurogenerics s.a. Brussels, Belgium) using the 1 mg 
formulation tablets. It was proposed to perform a catato-
nia test using LZP as first choice medication, as this is the 
medication that has been used most commonly in pediat-
ric catatonia.
The amount of drug given was based on the weight 
of the child. The lower dose (0.5 mg) was used as start-
ing dose for patients with <30 kg body weight, while the 
higher dose (1 mg) as the starting dose for patients with 
>30 kg body weight.
A positive response to a catatonia test consisted of a 
reduction in catatonic symptoms, 30 or 60 min later, by 
at least 50  % assessed by the KCP (using all 10 items). 
Positive responses were documented by video footage 
before and after administration of LZP.
If no response to the initial dose of LZP, was observed 
after 1  h, a second administration of the same medica-
tion at double the dose was given by AKM. Catatonia was 
again assessed by AKM at 30 and 60 min thereafter. If no 
response was observed, the test was considered negative.
Primary outcome measures
Our primary outcomes were: (a) the proportion of chil-
dren and adolescents with NS who met clinical criteria 
for pediatric catatonia; and (b) a positive catatonia test 
(>50  % reduction in catatonia symptoms and signs) on 
the responses of the children and adolescents with NS 
and catatonia to test doses of oral LZP.
Ethical considerations
Approval of the study was granted by the School of 
Medicine Research and Ethics Committee, Makerere 
University College of Health Sciences and the Uganda 
National Council of Sciences and Technology (Reference 
HS 1330). Written informed consent was obtained from 
the caregivers/parents. No assent was obtained from the 
children in view of their cognitive challenges.
Data analysis
Descriptive characteristics of the group of young people 
with NS and pediatric catatonia were analyzed according 
to socio-demographic characteristics, catatonia symp-
toms, lorazepam dosage and outcome. Results are sum-
marized as frequencies, proportions and means/medians 
as appropriate. Microsoft Excel for Mac 2011 software 
was used for analysis.
Table 1 Kampala catatonia panel consisting of ten screening items for catatonia
1 Excitement Extreme hyperactivity, constant motor unrest which is apparently non‑purposeful, includes aggressive 
episodes
2 Immobility‑stupor Extreme hypoactivity, remains in the same position for hours, immobility. Minimally responsive to stimuli
3 Mutism Verbally unresponsive or minimally responsive
4 Staring Fixed gaze, little or no visual scanning of environment, decreased blinking
5 Grimacing Facials spasms, facial tics, or maintenance of odd facial expressions
6 Echopraxia or echolalia Mimicking of examiner’s movements/speech
7 Rigidity Maintenance of a rigid position despite efforts to be moved
8 Negativism Apparently motiveless resistance to instructions or to attempts to move/examine the patient. Contrary 
behavior, does the opposite of the instruction
9 Active or passive refusal  
to eat or drink
Minimal or reduced food and fluid intake during the past week
10 Impulsivity Patient suddenly engages in inappropriate behavior (e.g., runs down the hallway, starts screaming, or takes 
off clothes) without provocation. Afterwards, cannot explain
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Results
Description of study participants
A total of 33 consecutive patients with confirmed NS 
from the villages of Bolo-Laming and Lagotoywech in 
Pader district were screened for catatonia over a two-day 
period. For details see Fig. 1. Sixteen children out of 33 
(48.5 %) had 2 or more catatonic symptoms on the KCP 
fulfilling the criteria for catatonia. Ten children were 
identified in the village of Bolo-Laming village and six 
in the village of Lagotoywech. There were 8 female and 8 
male NS children identified with Catatonia.
Age range was between 10 and 21  years with a mean 
age of 15 years (SD 2.95) and a mode and median age of 
15  years. Two children were in school, seven dropped 
out, and seven never went to school. Four children car-
ried a diagnosis of NS (without seizures) (see Table  2). 
Twelve children with NS had additional symptoms such 
as seizures or regression in growth or mental retardation. 
Ten children were taking sodium valproate and six chil-
dren carbamazepine. None of the children were febrile or 
had taken benzodiazepines during the last 2 days.
Evaluation for catatonia
Using the KCP 10-item list, the mean number of symp-
toms (with severity score of 2 or higher) per child was 5.4 
(range 2–8, SD 1.5). The highest scores were found for 
mutism, staring, poor eating/drinking, stupor, and gri-
macing. Excitement, rigidity, negativism and impulsivity 
had lower scores. None of the children had echolalia or 
echopraxia.
The number of children that received scores three 
or higher—indicating that symptoms were clearly pre-
sent—was 16 for staring, 12 for mutism, 11 for poor eat-
ing/drinking, 6 for both stupor and grimacing, 3 for both 
Fig. 1 Flowchart showing the recruitment and assessment of the study participants with catatonia
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excitement and impulsivity, 2 for negativism, nine for 
rigidity, and none for echolalia/echopraxia.
Drug administration of lorazepam
Twenty-two doses of LZP were administered; all 16 chil-
dren received an initial dose of 0.5 mg or 1 mg, depend-
ing on their weight. Six children received an increased 
second dose (1 or 2 mg) after 60 min when no changes in 
catatonia ratings had occurred in the previous hour.
Effects of lorazepam
In 11 children (>30 kg), the initial dose was 1 mg and in 5 
children (<30 kg) it was 0.5 mg. The changes in catatonia 
scores from baseline to 60 min after administration and 
the percent of reduction of catatonia scores are shown in 
Fig. 2a.
Following the first dose, in 6 children there was a 
reduction of more than 50  % in catatonia ratings, rep-
resenting a positive response. In 4 children there was a 
reduction in catatonia symptoms, however they did not 
reach the ratings of a positive catatonia test. Catatonia 
ratings decreased an average of 57 % in those 10 children 
whose catatonia ratings decreased. In 6 children, scores 
did not change and a repeat dose was given (see Fig. 2a, 
b).
In 5 children a repeat dose of 2 mg was given, and in 
one child the repeat dose was 1  mg. Scores at baseline 
and after 30′ and 60′ after the second dose are shown in 
Fig. 2b. Three children improved, two remained the same, 
and catatonia ratings increased in one child.
Side effects of the intervention
Focal seizures were observed in three children (CT002, 
CT004, and CT009) after administration of the dose of 
LZP. These seizures were clinically observed after the 
first dose in two children (CT002, CT004) and involved 
either one side of the lips and/or upper and lower limbs. 
No electroencephalographic equipment was available to 
verify these findings.
One child (CT009) became restless after administra-
tion of the 2 mg repeat dose, followed by a nodding epi-
sode. She then became drowsy and unresponsive. Her 
catatonia rating increased due to increased stupor that 
was probably related to seizure activity.
Four children had some sedation after the first 
dose. Four of the five children who were administered 
increased repeat doses had some sedation after 60′ of 
administration and some fell asleep later (see Table 2).
Discussion
This investigation was the first to attempt to formally 
assess for catatonia in NS. About half of a selected sam-
ple of children with NS that were screened for catatonia 
had two or more symptoms of catatonia and qualified for 
the diagnosis of catatonia. A mean number of 5 catatonic 
symptoms (range 2–8, SD 1.5) was found in those 16 
patients, most frequently mutism, staring, poor eating/
drinking, stupor, and grimacing. A few had excitement 
and showed impulsive behavior. None had echolalia or 
echopraxia. This finding is in line with previous studies 
showing that catatonic patients have usually more symp-
toms than the two symptoms that are needed to qualify 
for the diagnosis [20]. These findings raise the issue of 
a
b
Fig. 2 a Graph showing changes in catatonia scores with first dose 
of treatment after 60 min. b Graph showing the changes in catatonia 
scores with second dose of treatment after 30 and 60 min
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shared elements in the psychopathology of NS and cata-
tonia, and maybe in their aetiology and pathophysiology 
as well [17]. The clinical manifestations of NS also show 
resemblance with those of epilepsy, late-onset autism 
spectrum disorder, or early-onset schizophrenia.
Head nodding is considered the hallmark of NS. Some 
patients develop recurrent generalized tonic–clonic or 
focal seizures. The head nods are thought to be manifes-
tations of atonic seizures [1, 2, 22] but may also be viewed 
as a form of tic or stereotypy, a common autistic [23] 
and catatonic symptom [24]. The course of NS consists 
of a period of normal development, followed by onset of 
repetitive movements including head nodding, decreas-
ing social interaction & communication skills, and 
decline in intelligence & daily activities, similar as in late-
onset autism. The later onset of NS and period of normal 
development preclude a diagnosis of classic autism (that 
starts before or around age 3) yet the social withdrawal, 
speech and communication impairment, and repetitive 
movements are compatible with autism spectrum dis-
order [25]. In addition autistic and catatonic symptoms 
overlap [15, 26] and treatments that ameliorate catato-
nia seem to benefit patients who meet both criteria for 
autism spectrum disorders and onset of catatonia [27].
Some children with NS report hallucinations and 
become aggressive and/or self-injurious leaving a heavy 
burden on the family and caretakers [16]. Hallucina-
tions and behavioral problems are the hallmark of early-
onset schizophrenia, another disorder that shows clinical 
overlap with NS. Catatonic symptoms are thought to be 
common in early-onset schizophrenia [28]. There are 
currently no studies that have systematically assessed 
symptoms of schizophrenia or autism spectrum disorder 
in patients with NS.
The high occurrence of seizures in NS has prompted 
the notion that NS is a primary progressive epileptic dis-
order (of unknown origin) [1] yet not all NS cases have 
documented seizure activity and not all clinical features 
of NS may be linked to primary epilepsy [29]. In addition, 
the use of anti-epileptic drugs seems beneficial but not 
curative. It would be premature to dismiss clinical phe-
nomena such as catatonia or psychosis that do not easily 
fit the scope of primary progressive epilepsy especially as 
the aetiology and pathophysiology of NS remain obscure. 
Leads that NS is associated with current or prior infec-
tion with Onchocera volvulus, vitamin B6 or other vita-
min deficiencies need further study [30].
This investigation was also the first to assess the acute 
effects of single or repeated lorazepam treatment on NS. 
Catatonia ratings decreased in 10 of 16 patients after the 
first dose of LZP, with 6 patients having a score reduction 
of more than 50 % and being formal responders. Such a 
positive challenge test supports the presence of catatonia 
in the study subjects as it is known that catatonia is 
exquisitely responsive to benzodiazepines [21, 31].
Alternative explanations are that any improvements 
in NS by lorazepam or other benzodiazepines are more 
related to their anxiolytic or antiepileptic properties than 
their anti-catatonic effects. However, the effects of loraz-
epam and other benzodiazepines on catatonia may be 
linked through their anxiolytic and antiepileptic effects 
as extreme anxiety and subthreshold epileptic activity 
are among the putative mechanisms of catatonia [32, 33]. 
In addition, Musisi et al. [16, 34] have called attention to 
the association between NS and post-traumatic stress 
disorder as many children with NS have suffered consid-
erable war-related and other interpersonal trauma. Anxi-
ety- and stress-related symptoms in NS may respond to 
benzodiazepines in addition to psychomotor features of 
NS. Teasing out the effects of lorazepam on anxiety, epi-
leptic activity, and the motor symptoms of catatonia will 
require further studies. Regardless of the mechanism, 
findings of this pilot study beg the question whether 
treatment with lorazepam or another benzodiazepine 
in NS can have an important role in improving overall 
impairment in NS both in its acute and chronic stages.
Limitations
First, this was a feasibility study using a small number of 
patients hence the results should be interpreted with cau-
tion. Secondly, there is a potential that the NS cases were 
misclassified by the trained health worker as video-EEG/
EMG was not available in all cases. Thirdly, since the chil-
dren were mobilized to attend the treatment center by 
the village health workers, there is a potential of nonre-
sponse bias which may have excluded NS patients with 
catatonia who were unable to walk or travel to the treat-
ment center. Finally, the LZP trial was open and uncon-
trolled obscuring any placebo effects and/or any biases of 
non-blind assessments.
Conclusions
The findings from this pilot study suggest that a sig-
nificant proportion of children with NS, at least in this 
selected sample, meets criteria for catatonia, and that sin-
gle and repeated administration of LZP is safe and may 
be beneficial in NS. Acute but transient improvement of 
catatonia after administration of LZP supports and vali-
dates that catatonia is present, encouraging larger and 
longer studies of catatonia and LZP in NS management.
Larger, longer, and controlled studies are needed to 
verify the prevalence of catatonia in NS and to assess if 
repeated doses of LZP in NS sustain the clinical improve-
ments that are apparent after single doses of LZP. A next 
step is to systematically assess catatonia in a larger sam-
ple of children and adolescents with NS, to initiate LZP 
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in those who meet criteria for catatonia, to optimize the 
dose and administer LZP twice a day, and to continue 
treatment for 4–6  weeks. Ideally, an untreated control 
group would be enrolled using clinical catatonia assess-
ments done in a blind fashion.
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